Adage Capital reports 8.47% stake in Opus Genetics
Opus Genetics, Inc. Schedule 13G: Adage Capital Management and affiliated reporting persons report beneficial ownership of 6,029,775 shares of Common Stock, representing 8.47% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Opus Genetics, Inc. Schedule 13G: Adage Capital Management and affiliated reporting persons report beneficial ownership of 6,029,775 shares of Common Stock, representing 8.47% of the class. The percentage is calculated using 71,149,045 shares outstanding as of March 5, 2026.
The statement attributes shared voting and dispositive power over the 6,029,775 shares to Adage entities and to reporting persons Robert Atchinson and Phillip Gross. The filing includes a joint filing agreement executed by the reporting persons.
Insights
Adage reports an 8.47% passive/managed stake in Opus Genetics.
The filing shows 6,029,775 shares and a shared voting and dispositive power structure among Adage entities and named managers. The ownership percentage uses an explicit outstanding share base of March 5, 2026.
Cash‑flow treatment and intentions regarding potential sales or acquisitions are not stated; subsequent SEC filings would disclose any change in voting or disposition authority.
Schedule 13G reflects coordinated reporting by Adage and two individuals.
The joint filing agreement and signatures by Robert Atchinson and Phillip Gross indicate coordinated disclosure under beneficial‑owner reporting rules. The record cites shared powers rather than sole control.
Regulatory implications are routine: this is a reporting disclosure under Section 13 and does not itself change control; any future change in intent or ownership would require amended filings.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Adage Capital hold in Opus Genetics (IRD)?
Who are the named reporting persons in the Schedule 13G for IRD?
Does the filing state whether Adage has sole voting or dispositive power?
Does this Schedule 13G indicate Adage plans to change control of Opus Genetics?
AI-generated analysis. How Rhea-AI works. Not financial advice.